Breaking Finance News

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.

Boasting a price of $19.69, Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) traded 1.03% higher on the day. With the last stock price close up 21.88% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Amphastar Pharmaceuticals Inc has recorded a 50-day average of $19.31 and a two hundred day average of $16.16. Volume of trade was down over the average, with 311,932 shares of AMPH changing hands under the typical 587,646

Zacks Investment Research has downgraded Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) to Hold in a statement released on 10/10/2016.

On 8/09/2016, Needham released a statement for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) bumped up the target price from $20.00 to $22.00 that suggested an upside of 0.37%.

Performance Chart

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH)

With a total market value of $0, Amphastar Pharmaceuticals Inc has PE ratio of 63.93 with a one year low of $10.50 and a one year high of $21.53 .

A total of 5 analysts have released a report on Amphastar Pharmaceuticals Inc. zero analysts rating the company a strong buy, zero brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell with a average stock price target of $17.80.

General Information About Amphastar Pharmaceuticals Inc (NASDAQ:AMPH)

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company manufactures and sells approximately 20 products. Additionally, the Company is developing a portfolio of approximately 10 generic abbreviated new drug applications (ANDA), over three generic biosimilar and over six injectable and inhalation product candidates.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.